Patents Assigned to Les Laboratoires Servier
  • Patent number: 12221462
    Abstract: The present disclosure concerns dosages for the treatment of human patients susceptible to or diagnosed with a disease, such as cancer. Provided are methods for administering chimeric antigen receptor (CAR)-T cells. Also provided are compositions and articles of manufacture for use in the methods.
    Type: Grant
    Filed: October 10, 2023
    Date of Patent: February 11, 2025
    Assignees: Allogene Therapeutics, Inc., Les Laboratoires Servier
    Inventors: Cyril Alkis Konto, Amina Zinai
  • Publication number: 20240376094
    Abstract: The present disclosure provides PROTAC compounds represented by Formula (A): D-L-DSM (A), or an enantiomer, a diastereoisomer, and/or a pharmaceutically acceptable salt of any one of the foregoing, wherein: DSM is a degradation signaling compound {e.g., an E3 ubiquitin ligase recruitment ligand, such as a CRBN ligand or a VHL ligand) covalently attached to a linker L; L is a linker that covalently attaches DSM to D; and D is a Bcl-xL inhibitor compound of Formula (I) or Formula (II) covalently attached to the linker L: (I); (II) wherein the definitions for the variables are described herein. Also provided are pharmaceutical compositions comprising the PROTAC compounds of the present disclosure and methods of use and methods of making thereof.
    Type: Application
    Filed: February 1, 2022
    Publication date: November 14, 2024
    Applicants: Les Laboratoires Servier, Novartis AG
    Inventors: András Herner, Piroska Markacz, Gang Liu, Katsumasa Nakajima, Tibor Novak, Georges-Alain Franzetti, Jérôme-Benoit Starck, Frédéric Colland, Patrice Desos, Attila Paczal, Bianka Szokol, Mátyás Timari, Vilibald Kun, Matthew Burger, Joseph D'Alessio, Katherine Seiss, Ranny Thomas, Liang Zhao
  • Publication number: 20220195035
    Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
    Type: Application
    Filed: March 7, 2022
    Publication date: June 23, 2022
    Applicants: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
  • Publication number: 20200002413
    Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
    Type: Application
    Filed: June 28, 2019
    Publication date: January 2, 2020
    Applicants: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
  • Patent number: 10385124
    Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: August 20, 2019
    Assignees: Les Laboratoires Servier, Institut National de la Santè, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
  • Patent number: 10385125
    Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: August 20, 2019
    Assignees: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
  • Patent number: 10385126
    Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: August 20, 2019
    Assignees: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
  • Patent number: 10377821
    Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: August 13, 2019
    Assignees: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
  • Patent number: 10370444
    Abstract: The present disclosure provides methods and compositions useful for preventing gastrointestinal and/or colorectal cancer in animals, including humans, having pre-cancerous adenomatous polyps. The present disclosure provides compositions comprising anti-PG antibodies suitable for use in the methods of the disclosure. The present disclosure also provides methods and compositions useful for monitoring the efficacy of anti-PG treatment in subjects with pre-cancerous polyps.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: August 6, 2019
    Assignees: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Leila Houhou, Mathieu Petremann, Dominique Joubert, Frédéric Hollande
  • Publication number: 20160168077
    Abstract: The present invention relates to new forms of co-crystals of agomelatine and p-toluenesulphonic acid, to a process for their preparation and to pharmaceutical compositions containing them. The co-crystals according to the invention have better solubility than agomelatine and are therefore more suitable for the preparation of pharmaceutical compositions. They also have better stability and purity and, moreover, are obtained by a simple process which does not include any difficult steps.
    Type: Application
    Filed: July 30, 2014
    Publication date: June 16, 2016
    Applicant: Les Laboratoires Servier
    Inventors: Hanbin SHAN, Yuhui SHEN, Ying LUO, Philippe LETELLIER, Michael LYNCH
  • Publication number: 20160152599
    Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R3, R4, R5, A1, A2, T and W are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.
    Type: Application
    Filed: July 22, 2014
    Publication date: June 2, 2016
    Applicants: Les Laboratoires Servier, Vernails (R&D) Limited
    Inventors: Patrick CASARA, Thierry LE DIGUARHER, Jean-Michel HENLIN, Jéröme-Benoit STARCK, Arnaud LE TIRAN, Guillaume DE NANTEUIL, Olivier GENESTE, James Edward Paul DAVIDSON, James Brooke MURRAY, I-Jen CHEN, Claire WALMSLEY, Christopher John GRAHAM, Stuart RAY, Daniel MADDOX, Simon BEDFORD
  • Patent number: 8940785
    Abstract: Association between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, and an acetylcholinesterase inhibitor. Medicinal products containing the same which are useful in the treatment of cognitive disturbances associated with cerebral ageing and with neurodegenerative diseases.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: January 27, 2015
    Assignee: Les Laboratoires Servier
    Inventors: Caryn Trocme-Thibierge, Aurore Sors, Florence Keime-Guibert
  • Patent number: 8927708
    Abstract: Process for the synthesis of the compound of formula (I): wherein R represents a para-methoxybenzyl (PMB) group or the following group: Application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: January 6, 2015
    Assignee: Les Laboratoires Servier
    Inventor: Alexandre Le Flohic
  • Patent number: 8921409
    Abstract: Combination between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, and an NMDA glutamatergic receptor antagonist. Medicinal products containing the same which are useful in the treatment of cognitive disturbances associated with cerebral ageing and neurodegenerative diseases.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: December 30, 2014
    Assignee: Les Laboratoires Servier
    Inventors: Aurore Sors, Caryn Trocme-Thibierge, Annette Merdes
  • Patent number: 8883199
    Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterized in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: November 11, 2014
    Assignees: Les Laboratoires Servier, Pharmacyclics, Inc.
    Inventors: Ioana Kloos, Renata Robert, Anne Jacquet-Bescond, Stephane Depil, Marylore Chenel, Sylvain Fouliard, Sriram Balasubramanian
  • Patent number: 8865915
    Abstract: Process for the preparation of the compound of formula (I):
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: October 21, 2014
    Assignee: Les Laboratoires Servier
    Inventors: Julie Linol, Stéphane Laurent, Arnaud Grenier, Sébastien Mathieu
  • Patent number: 8859763
    Abstract: Process for the synthesis of the compound of formula (I): Application in the synthesis of ivabradine, addition salts thereof with a pharmaceutically acceptable acid and hydrates thereof.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: October 14, 2014
    Assignee: Les Laboratoires Servier
    Inventors: Lucile Vaysse-Ludot, Alexandre Le Flohic, Michel Vaultier, Mathieu Pucheault, Thomas Kaminski
  • Patent number: 8853198
    Abstract: The present invention relates to 1,4-benzothiazepine derivatives and their use to treat conditions, disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also discloses pharmaceutical compositions comprising the compounds and uses thereof to treat diseases and conditions associated with RyRs, in particular cardiac, musculoskeletal and central nervous system (CNS) disorders.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: October 7, 2014
    Assignees: Les Laboratoires Servier, ARMGO Pharma, Inc.
    Inventors: Jiaming Yan, Sandro Belvedere, Yael Webb, Marc Bertrand, Nicole Villeneuve
  • Patent number: 8853449
    Abstract: Process for the industrial synthesis of the compound of formula (I)
    Type: Grant
    Filed: January 4, 2012
    Date of Patent: October 7, 2014
    Assignee: Les Laboratoires Servier
    Inventors: Samir Zard, Béatrice Sire, Mehdi Boumediene
  • Patent number: 8835652
    Abstract: Delta crystalline form of the compound of formula (I): characterised by its X-ray powder diffraction diagram. Medicinal products containing the same which are useful in the treatment of cardiovascular diseases.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: September 16, 2014
    Assignee: Les Laboratoires Servier
    Inventors: Julie Linol, Stephane Laurent, Arnaud Grenier, Sebastien Mathieu